ArticleEuropean journal of case reports in internal medicine2025
Nivolumab-Induced Chylothorax in A Patient with Advanced Gastric Adenocarcinoma.
Article in European journal of case reports in internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chylothorax refers to the presence of chyle in the pleural space leading to respiratory compromise. Chylothorax secondary to gastric adenocarcinoma or immune checkpoint inhibitors, such as nivolumab, is exceedingly rare and has been documented only in isolated case reports. The exact mechanism by which nivolumab may induce chylothorax remains unclear, though immune-mediated increased lymphatic permeability induced by anti-PD-1 has been hypothesised. This report highlights a unique presentation of chylothorax in a patient with gastric adenocarcinoma undergoing nivolumab therapy. LEARNING POINTS: Chylothorax can be a rare immune-related adverse event of nivolumab.In differentiating between malignant chylothorax in advanced malignancy and immune-related adverse events, chylothorax can be difficult. Negative pleural cytology, lack of thoracic duct obstruction and response to immunotherapy can guide clinicians in attributing the cause, which is essential for making decisions about continuing or discontinuing immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.